Lung Cancer Clinical Trials in Nashville

Showing 101-120 of 795 trials

A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies

NCT04678648

RSC-101 is a Phase 1a/1b clinical trial of RSC-1255 in adult study participants with advanced solid tumor malignancies who are intolerant of existing therapies known to provide clinical benefit, have disease that has progressed after standard therapy, or have previously failed other therapies. The study has two phases. The purpose of Phase 1a (Dose Escalation) is to confirm the appropriate treatment dose and Phase 1b (Dose Expansion) is to characterize the safety and efficacy of RSC-1255.

Advanced Malignant Solid NeoplasmRAS MutationLung Cancer+3 more

RasCal Therapeutics, Inc.134 participantsStarted Mar 2021

Los Angeles, California, United States • Denver, Colorado, United States • Nashville, Tennessee, United States

RECRUITINGPhase 1< 1 mile

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

NCT06625775

First in human study to evaluate the safety, tolerability, and pharmacokinetics (PK) of BBO-10203, a PI3Kα:RAS breaker, alone and in combination with other anti-cancer agents in patients with advanced solid tumors.

Solid Tumor, AdultMetastatic Breast CancerAdvanced Breast Cancer+8 more

TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)392 participantsStarted Oct 2024

Los Angeles, California, United States • San Diego, California, United States • San Francisco, California, United States +29 more locations

A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

Lung Cancer Trials in Other Cities

A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab

Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)

Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors

Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor

Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway

Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

Biomarker Directed Trial of Temozolomide and Stenoparib in Relapsed SCLC

Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON)

Empathic Communication Skills (ECS) Training

Beamion LUNG-3: A Study to Test Whether Zongertinib Helps People With Surgically Removed, Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment

IBI363 vs Docetaxel in Patients With Advanced Squamous Lung Cancer After Standard Treatments Have Failed

A Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in Participants With Previously Untreated Locally Advanced Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer

Phase 1b/2 Platform Study of Select Immunotherapy Combinations in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)

A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer

STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers

Other Conditions in Nashville